case_images: PMC11834120_01
case_images: NM PET-CT before (A) and after (B) treatment with carboplatin, paclitaxel, and atezolizumab. Image (A) is remarkable for FDG-avid right hilar mass (white arrow) measuring 8.5 x 6.8 x 6.3 cm with SUV max of 11.3. Image (B) shows decreasing patchy consolidation in the right infrahilar region (green arrow) without significant focal uptake, SUV max of 1.9, previously 2.5, and new FDG avid left adrenal mass (red arrow) suspicious for metastasis. . NM PET-CT: nuclear medicine positron emission tomography-computed tomography; FDG: F-18 fluorodeoxyglucose
case_images: cureus-0017-00000077652-i01.jpg
case_images: PMC11834120_01_cureus-0017-00000077652-i01.jpg
case_images: FIG1
case_images: A follow-up positron emission tomography-computed tomography (PET-CT) showed a response, but a new left adrenal mass was suspicious of metastasis (Figure 1). 
case_images: CT scan before (A) and two months after (B) treatment with capmatinib. Left adrenal mass size decreased from 4.56 x 2.97 cm to 3.49 x 2.20 cm. . CT: computed tomography
case_images: cureus-0017-00000077652-i02.jpg
case_images: PMC11834120_01_cureus-0017-00000077652-i02.jpg
case_images: FIG2
case_images: The patient initially tolerated the capmatinib, and a repeated CT scan showed decreased left adrenal mass size after two months (Figure 2).